Hereditary Angioedema Therapeutic Market Demands, Growth Analysis, Industry Report 2023-2028

How Big is the Hereditary Angioedema Therapeutic Market ? :

IMARC Group’s latest report, titled “Hereditary Angioedema Therapeutic Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on the hereditary angioedema therapeutic market Share. The report also includes competitor and regional analysis, and contemporary advancements in the market. the global hereditary angioedema therapeutic market size reached US$ 2.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2028, exhibiting a growth rate (CAGR) of 8.4% during 2023-2028.

What are Hereditary Angioedema Therapeutic and Uses ? :

Hereditary angioedema (HAE) is a rare genetic disorder that is caused by a deficiency or dysfunction of C1 esterase inhibitor (C1-INH), leading to recurrent episodes of swelling in different body parts. Hereditary Angioedema (HAE) therapeutics are focused on the prevention and treatment of acute attacks, aiming on long-term prophylaxis to reduce the frequency and severity of attacks.

These therapeutics function by targeting the bradykinin pathway to regulate its activity by blocking the bradykinin receptor or inhibiting the enzymes involved in its production. The primary treatment options for HAE include C1 esterase inhibitor replacement therapy, Bradykinin receptor antagonists, and Kallikrein inhibitors.

Request Free Sample Report (Exclusive Offer on this report): https://www.imarcgroup.com/hereditary-angioedema-therapeutic-market/requestsample

Who are the key Players Operating in the Industry ? :

The competitive landscape of the industry has also been examined along with the profiles of the key players being

• Adverum Biotechnologies Inc

• Amgen Inc

• Attune Pharmaceuticals

• BioCryst Pharmaceuticals Inc

• Centogene N.V

• CSL Limited

• Ionis Pharmaceuticals Inc

• KalVista Pharmaceuticals Inc

• Novartis AG

• Pharming Group N.V

• Sanofi S.A

• Takeda Pharmaceutical Company Limited

What are the Growth Prospects and Trends in the Hereditary Angioedema Therapeutic Industry ? :

The global market is primarily driven by the increasing prevalence of hereditary angioedema among the masses. In line with this, continual advancements in the treatment of hereditary angioedema such as the development of gene therapies, novel drug formulations and targeted therapies are fueling the market. Moreover, the introduction of innovative drug delivery systems such as the introduction of subcutaneous C1 esterase inhibitor formulations facilitating self-administration is providing an impetus to the market.

Furthermore, favorable government reimbursement policies and modernization of healthcare facilities in several countries is creating a positive market outlook. Some of the other factors contributing to the market include extensive research and development (R&D) activities, considerable rise in healthcare expenditure, and strategic partnerships among pharmaceutical companies and healthcare organizations.

Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/hereditary-angioedema-therapeutic-market

What is Included in Market Segmentation ? :

The report has segmented the market into the following categories:

Breakup by Type:

• Type I Hereditary Angioedema

• Type II Hereditary Angioedema

• Type III Hereditary Angioedema

Breakup by Drug Class:

• C1-Esterase Inhibitor

• Bradykinin B2 Receptor Antagonist

• Kallikrein Inhibitor

• Others

Breakup by Treatment Type:

• Prophylaxis Treatment

• On-demand Treatment

Breakup by Route of Administration:

• Intravenous

• Subcutaneous

• Oral

Breakup by End User:

• Hospitals

• Clinics

• Home Healthcare

• Others

Breakup by Region:

• North America (United States, Canada)

• Europe (Germany, France, United Kingdom, Italy, Spain, Others)

• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)

• Latin America (Brazil, Mexico, Others)

• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key Highlights of the Report:

• Market Performance (2017-2022)

• Market Outlook (2023-2028)

• Porter’s Five Forces Analysis

• Market Drivers and Success Factors

• SWOT Analysis

• Value Chain

• Comprehensive Mapping of the Competitive Landscape

 Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: [email protected]

Follow us on Twitter: @imarcglobal

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/